Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02926352 · ClinicalTrials.gov registry record · Phase 1

Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training

A Phase 1 study, sponsored by University of Texas at Austin.

Completed
Registry status
Phase 1
Development phase
112
Enrollment target

NCT02926352: Completed Phase 1 study, sponsored by University of Texas at Austin.

NCT02926352 is a Phase 1 study that has completed, run by University of Texas at Austin. The registered enrollment target is 112 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02926352, a Phase 1 study, has completed, sponsored by University of Texas at Austin.

COMPLETED
Registry status
Phase 1
Development phase
112 participants
Enrollment target

Study Summary

There are two specific aims for this study. Aim 1 is to test whether low-level laser therapy (LLLT) can enhance the efficacy of fear extinction training in the modification of pathological fear. Aim 2 is to investigate the efficacy of low-level laser therapy (LLLT) as a stand-alone intervention for anxiety/phobias.

Primary Outcome

Change in fear response as indicated by behavioral approach and peak subjective fear ratings (0-100) in a generalization context (different from the treatment context) from baseline to follow-up.

Interventions

  • BEHAVIORAL Extinction Training
  • DEVICE Low-Level Laser Therapy
  • DEVICE Sham Low-Level Laser Therapy

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2015-08-01
Est. Completion 2020-05-04
Phase Phase 1
University of Texas at Austin

257 total trials

What the finished NCT02926352 record still lists

NCT02926352 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher).

The record links to 0 conditions, and to 3 interventions - of which Extinction Training is the first listed.

NCT02926352 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02926352 about?

NCT02926352 is a clinical study titled "Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training". There are two specific aims for this study. Aim 1 is to test whether low-level laser therapy (LLLT) can enhance the efficacy of fear extinction training in the modification of pathological fear. Aim 2 is to investigate the efficacy of low-level laser therapy (LLLT) as a stand-alone intervention for ...

What is the current status of trial NCT02926352?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2015-08-01. Estimated completion is 2020-05-04.

What interventions are being tested in trial NCT02926352?

The interventions under investigation include: Extinction Training (BEHAVIORAL), Low-Level Laser Therapy (DEVICE), Sham Low-Level Laser Therapy (DEVICE).

Who is sponsoring clinical trial NCT02926352?

This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02926352's enrollment target sits among peer trials

112 508th of 2000 higher than 1,489 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04511013 · 112 participants · Phase 2

    A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • NCT04551560 · 112 participants · NA

    Stress and Congestive Heart Failure

  • NCT04872166 · 112 participants · Phase 1

    A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

  • NCT05024773 · 112 participants · Phase 3

    Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02926352, the US trial registry maintained by the National Library of Medicine. NCT02926352 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.